I've never had dengue — should I still get the vaccine before my Bali trip?

ATAGI recommends QDENGA for people without prior dengue who are planning prolonged or repeated stays in endemic regions. For shorter one-off trips, it can be considered after an individual risk-benefit discussion with your GP or travel medicine clinician — the length of your stay, how much time you'll spend outdoors in peak mosquito hours, and your overall health picture all factor in. There's no absolute cut-off; the conversation is worth having at your travel consult.

Does getting the vaccine mean I can stop worrying about mosquito repellent?

No. QDENGA reduces your risk of dengue substantially but does not eliminate it. Standard travel health advice — repellent containing DEET or picaridin, long sleeves during dusk and dawn, and accommodation with screens or air conditioning — applies alongside vaccination, not instead of it. The vaccine is an additional layer, not a replacement for bite prevention.

Can I get QDENGA if I'm pregnant?

Pregnancy is a relative contraindication. QDENGA is not routinely recommended during pregnancy because it is a live-attenuated vaccine. If you are pregnant and travel to an endemic area is unavoidable, an individual risk-benefit discussion with your GP or obstetrician is warranted. In most circumstances, travel planning rather than vaccination is the safer primary approach.

Australia's first dengue vaccine is now available on prescription

Summer is six weeks away. If you are planning a trip to Bali, Thailand, Vietnam, India, or Fiji this season — five of Australia’s ten most-visited international destinations, and all areas with frequent dengue transmission — there is now something new to discuss at your travel consult.

Australia’s first dengue vaccine, QDENGA, is now available on private prescription for people aged four and older. The live-attenuated tetravalent vaccine, developed by Takeda, covers all four dengue serotypes. After years of having no dengue vaccine option in Australian general practice, there is now a tool.

That is a genuine shift. It is also worth understanding what the tool actually is, who it is recommended for, and what it cannot do.

What is dengue and why does it matter for Australian travellers?

Dengue fever is a mosquito-transmitted viral illness caused by one of four serotypes of the dengue virus. It is endemic across tropical and subtropical Asia, the Pacific, and parts of Latin America — which maps almost exactly onto the destinations Australians travel to most. The disease ranges from a self-limiting febrile illness to severe dengue, characterised by haemorrhage, plasma leakage, and organ impairment, which can be fatal without supportive hospital care.

There is no specific antiviral treatment for dengue. Management is supportive — fluids, monitoring, pain relief (not NSAIDs or aspirin, which increase bleeding risk). Prevention is the entire clinical lever. Mosquito avoidance has been the only tool available to Australian GPs in the travel medicine setting until now.

What QDENGA is and what the trial data shows

QDENGA is a live-attenuated vaccine, meaning it uses a weakened but replicating form of the dengue virus. Two 0.5mL subcutaneous injections are given at least 12 weeks apart. Single-dose efficacy is 82% against virologically confirmed dengue at three months post-vaccination, with 75% protection against dengue-related hospitalisation. The two-dose course achieves 80.2% overall efficacy at 12 months in phase 3 trial data.

These are meaningful numbers in a disease with no treatment option beyond supportive care. For reference, this sits in the same efficacy range as well-matched influenza vaccines. Protection varies by dengue serotype across the four strains, but the broad tetravalent coverage is precisely the point — natural dengue infection with one serotype does not protect against the others.

Who ATAGI recommends it for

The Australian Technical Advisory Group on Immunisation has released two-tier guidance.

Strongly recommended: travellers aged four and older with a confirmed or likely prior dengue infection who are heading to an endemic area. Importantly, routine serology to confirm prior infection is not required — clinical history of prior dengue, or a credible travel history to a highly endemic region, is sufficient. This avoids the practical barrier of blood testing before every travel consult.

Recommended: people without prior dengue infection who are planning prolonged or repeated stays in high-risk areas. The efficacy data is strong for this group, though slightly more conservative recommendations reflect that the evidence base is largest in those with prior immune exposure.

Can be considered on individual risk-benefit assessment: shorter-trip travellers without prior dengue. Length of stay, degree of outdoor exposure, and individual circumstances all inform the conversation.

What it cannot do — and who should not have it

QDENGA is contraindicated in immunocompromised individuals and those requiring immunosuppressive treatment within four weeks. Pregnancy is a relative contraindication: as a live vaccine, it is not routinely recommended during pregnancy, though individual risk-benefit assessment applies when travel to endemic areas is unavoidable.

The vaccine does not replace mosquito bite prevention. Repellent containing DEET or picaridin, long sleeves during peak mosquito hours (dusk and dawn), and accommodation with screens or air conditioning remain standard travel health advice alongside vaccination — not instead of it. Minimum 15 minutes observation after injection is recommended given post-marketing reports of hypersensitivity reactions.

The cost reality

QDENGA is a private-prescription item. It is not currently funded on the National Immunisation Program or the Pharmaceutical Benefits Scheme. Patients pay out-of-pocket through their GP or travel medicine clinic. Private-prescription vaccines can run to several hundred dollars per dose across a two-dose course, which places this outside reach for some travellers who could genuinely benefit.

This is the friction point between a sound ATAGI recommendation and equitable implementation. It deserves honest discussion in the consult, and it will be a legitimate argument for advocates pursuing PBS listing through the standard channels.

Both sides of this

The case for recommending QDENGA to appropriate patients is clear: an 80% efficacy vaccine against a disease with no treatment and meaningful hospitalisation risk, in destinations millions of Australians visit every year. That is a straightforward clinical advance.

The hesitation, where it exists, is about cost and access rather than evidence. Unlike some new vaccines where the trial data warrants caution, QDENGA’s efficacy and safety profile are well-characterised from phase 3 data. The uncertainty here is not scientific — it is economic and logistical.

2 cents

If you are planning international travel this summer to any dengue-endemic destination, add QDENGA to the list of things to discuss at your pre-travel appointment. Bring up whether you have had dengue before — even a mild febrile illness during previous travel may count. If your GP recommends two doses, plan for the timing: the course requires at least 12 weeks between injections, so December travel means starting now.

Verdict: yes — worth knowing about.

Sources cited

Dengue vaccine lands for Australian travellers — Medical Republic, 30 September 2026